Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 31
Filtrar
1.
RMD Open ; 9(3)2023 08.
Artículo en Inglés | MEDLINE | ID: mdl-37558492

RESUMEN

OBJECTIVES: We aimed to describe patients with autoimmune diseases (AID) developing invasive fungal disease (IFD) and identify factors associated with short-term mortality. METHODS: We analysed cases of IFD associated with AID from the surveillance network of invasive fungal diseases (Réseau de surveillance des infections fongiques invasives, RESSIF) registry of the French national reference centre for invasive mycoses. We studied association of AID-specific treatments with 30-day mortality. We analysed total lymphocyte and CD4-T cell counts in patients with Pneumocystis jirovecii pneumonia (PCP). RESULTS: From 2012 to 2018, 549 individuals with IFD and AID were included, mainly with PCP (n=227, 41.3%), fungemia (n=167, 30.4%) and invasive aspergillosis (n=84, 15.5%). Rheumatoid arthritis (RA) and anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV) were the most frequent AID in PCP (n=55 and 25, respectively) and invasive aspergillosis (n=15 and 10, respectively), inflammatory bowel diseases (IBDs) were predominant in fungemia (n=36). At IFD diagnosis, 365 (66.5%) patients received glucocorticoids (GCs), 285 (51.9%) immunosuppressants, 42 (7.7%) tumor necrosis factor (TNF)-α blockers, 75 (13.7%) other biologics. Mortality at 30 days was 28.1% (143/508). Fungemia and high-dose GCs were independently associated with higher 30-day mortality. In PCP patients, lymphopenia <1500/mm3 was frequent (132/179, 73.7%) even if CD4+T cell count exceeded 200/mm3 in 56/78 patients (71.8%) (median 472.5/mm3, IQR 160-858). CONCLUSION: IFD associated with AID occurs primarily in RA, AAV and IBD, especially when treated with GCs and immunosuppressants. Mortality is high, especially for patients on high-dose GCs. Lymphopenia may help identify risk of PCP, but normal CD4+T cell count does not rule out the risk. Further studies are needed to assess the individual risk factors for IFD.


Asunto(s)
Enfermedades Autoinmunes , Infecciones Fúngicas Invasoras , Enfermedades Autoinmunes/complicaciones , Enfermedades Autoinmunes/terapia , Infecciones Fúngicas Invasoras/complicaciones , Infecciones Fúngicas Invasoras/epidemiología , Infecciones Fúngicas Invasoras/etiología , Infecciones Fúngicas Invasoras/mortalidad , Humanos , Masculino , Femenino , Persona de Mediana Edad , Anciano , Glucocorticoides/efectos adversos , Glucocorticoides/uso terapéutico , Inmunosupresores/efectos adversos , Inmunosupresores/uso terapéutico , Factores de Riesgo , Francia , Prevalencia
2.
mBio ; 13(3): e0092022, 2022 06 28.
Artículo en Inglés | MEDLINE | ID: mdl-35499498

RESUMEN

The French National Reference Center for Invasive Mycoses and Antifungals leads an active and sustained nationwide surveillance program on probable and proven invasive fungal diseases (IFDs) to determine their epidemiology in France. Between 2012 and 2018, a total of 10,886 IFDs were recorded. The incidence increased slightly over time (2.16 to 2.36/10,000 hospitalization days, P = 0.0562) in relation with an increase of fungemia incidence (1.03 to 1.19/10,000, P = 0.0023), while that of other IFDs remained stable. The proportion of ≥65-year-old patients increased from 38.4% to 45.3% (P < 0.0001). Yeast fungemia (n = 5,444) was due mainly to Candida albicans (55.6%) with stable proportions of species over time. Echinocandins became the main drug prescribed (46.7% to 61.8%), but global mortality rate remained unchanged (36.3% at 1 month). Pneumocystis jirovecii pneumonia (n = 2,106) was diagnosed mostly in HIV-negative patients (80.7%) with a significantly higher mortality than in HIV-positive patients (21.9% versus 5.4% at 1 month, P < 0.0001). Invasive aspergillosis (n = 1,661) and mucormycosis (n = 314) were diagnosed mostly in hematology (>60% of the cases) with a global mortality rate of 42.5% and 59.3%, respectively, at 3 months and significant changes in diagnosis procedure over time. More concurrent infections were also diagnosed over time (from 5.4% to 9.4% for mold IFDs, P = 0.0115). In conclusion, we observed an aging of patients with IFD with a significant increase in incidence only for yeast fungemia, a trend toward more concurrent infections, which raises diagnostic and therapeutic issues. Overall, global survival associated with IFDs has not improved despite updated guidelines and new diagnostic tools. IMPORTANCE The epidemiology of invasive fungal diseases (IFDs) is hard to delineate given the difficulties in ascertaining the diagnosis that is often based on the confrontation of clinical and microbiological criteria. The present report underlines the interest of active surveillance involving mycologists and clinicians to describe the global incidence and that of the main IFDs. Globally, although the incidence of Pneumocystis pneumonia, invasive aspergillosis, and mucormycosis remained stable over the study period (2012 to 2018), that of yeast fungemia increased slightly. We also show here that IFDs seem to affect older people more frequently. The most worrisome observation is the lack of improvement in the global survival rate associated with IFDs despite the increasing use of more sensitive diagnostic tools, the availability of new antifungal drugs very active in clinical trials, and a still low/marginal rate of acquired in vitro resistance in France. Therefore, other tracks of improvement should be investigated actively.


Asunto(s)
Aspergilosis , Fungemia , Infecciones Fúngicas Invasoras , Mucormicosis , Neumonía por Pneumocystis , Anciano , Antifúngicos/uso terapéutico , Aspergilosis/tratamiento farmacológico , Aspergilosis/epidemiología , Fungemia/tratamiento farmacológico , Humanos , Infecciones Fúngicas Invasoras/epidemiología , Mucormicosis/tratamiento farmacológico , Espera Vigilante
4.
PLoS One ; 14(4): e0215070, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30995270

RESUMEN

To study the anatomo-biochemical substrates of brain inflammatory processes, Wistar male rats were infected with Trypanosoma brucei brucei. With this reproducible animal model of human African trypanosomiasis, brain cells (astrocytes, microglial cells, neurons) expressing the inducible nitric oxide synthase (iNOS) enzyme were revealed. Immunohistochemistry was achieved for each control and infected animal through eight coronal brain sections taken along the caudorostral axis of the brain (brainstem, cerebellum, diencephalon and telencephalon). Specific markers of astrocytes (anti-glial fibrillary acidic protein), microglial cells (anti-integrin alpha M) or neurons (anti-Neuronal Nuclei) were employed. The iNOS staining was present in neurons, astrocytes and microglial cells, but not in oligodendrocytes. Stained astrocytes and microglial cells resided mainly near the third cavity in the rostral part of brainstem (periaqueductal gray), diencephalon (thalamus and hypothalamus) and basal telencephalon. Stained neurons were scarce in basal telencephalon, contrasting with numerous iNOS-positive neuroglial cells. Contrarily, in dorsal telencephalon (neocortex and hippocampus), iNOS-positive neurons were plentiful, contrasting with the marked paucity of labelled neuroglial (astrocytes and microglial) cells. The dual distribution between iNOS-labelled neuroglial cells and iNOS-labelled neurons is a feature that has never been described before. Functionalities attached to such a divergent distribution are discussed.


Asunto(s)
Astrocitos/enzimología , Cerebelo/enzimología , Microglía/enzimología , Neuronas/enzimología , Óxido Nítrico Sintasa de Tipo II/metabolismo , Trypanosoma brucei brucei/enzimología , Tripanosomiasis Africana/enzimología , Animales , Astrocitos/parasitología , Células Cultivadas , Cerebelo/parasitología , Masculino , Microglía/parasitología , Neuronas/parasitología , Ratas , Ratas Wistar , Tripanosomiasis Africana/parasitología
5.
J Clin Microbiol ; 51(7): 2379-81, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23554207

RESUMEN

Arginase serum levels were increased in human African trypanosomiasis patients and returned to control values after treatment. Arginase hydrolyzes l-arginine to l-ornithine, which is essential for parasite growth. Moreover, l-arginine depletion impairs immune functions. Arginase may be considered as a biomarker for treatment efficacy.


Asunto(s)
Arginasa/sangre , Biomarcadores/sangre , Monitoreo de Drogas/métodos , Tripanosomiasis Africana/tratamiento farmacológico , Femenino , Humanos , Masculino , Suero/química , Resultado del Tratamiento
6.
Res Rep Trop Med ; 3: 35-45, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-30890865

RESUMEN

Human African trypanosomiasis (HAT) is caused by the injection of Trypanosoma brucei (T. b.) gambiense or T. b. rhodesiense by Glossina, the tsetse fly. Three historical eras followed the exclusive clinical approach of the 19th century. At the turn of the century, the "initial research" era was initiated because of the dramatic spread of HAT throughout intertropical Africa, and scientists discovered the agent and its vector. Two entities, recurrent fever and sleeping sickness, were then considered a continuum between hemolymphatic stage 1 and meningoencephalitic stage 2. Treatments were developed. Soon after World War I, specific services and mobile teams were created, initiating the "epidemiological" era, during which populations were visited, screened, and treated. As a result, by 1960, annual new cases were rare. New mass screening and staging tools were then developed in a third, "modern" era, especially to counter a new epidemic wave. Currently, diagnosis still relies on microscopic detection of trypanosomes without (wet and thick blood films) or with concentration techniques (capillary tube centrifugation, miniature anion-exchange centrifugation technique). Staging is a vital step. Stage 1 patients are treated on site with pentamidine or suramin. However, stage 2 patients are treated in specialized facilities, using drugs that are highly toxic and/or that require complex administration procedures (melarsoprol, eflornithine, or nifurtimox-eflornithine combination therapy). Suramin and melarsoprol are the only medications active against Rhodesian HAT. Staging still relies on cerebrospinal fluid examination for trypanosome detection and white blood cell counts: stage 1, absence of trypanosomes, white blood cell counts ≤ 5/µL; stage 2, presence of trypanosomes, white blood cell counts ≥ 20/µL; T. b. gambiense HAT intermediate stage, between these still controversial thresholds. Our group has proposed the use of noninvasive ambulatory polysomnography to identify sleep-wake abnormalities characteristic of stage 2 of the disease. Only patients with abnormal sleep-wake patterns would then undergo confirmative lumbar puncture.

7.
J Neurol Sci ; 305(1-2): 112-5, 2011 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-21470639

RESUMEN

Gambian (Trypanosoma brucei gambiense) human African trypanosomiasis (HAT) evolves from the hemolymphatic stage 1, treated with pentamidine, to the meningoencephalitic stage 2, often treated with melarsoprol. This arseniate may provoke a deadly reactive encephalopathy. It is therefore crucial to diagnose precisely the stages of HAT, especially when clinical and biological examinations are doubtful. We present here the case of a 30-month old girl (E20 KOLNG) diagnosed with stage 1 HAT during a field survey in June 2007 in Congo. She was followed-up every six months for 18 months in a village dispensary facility at Mpouya. Her health status deteriorated in December 2008, although cerebrospinal fluid (CSF) white blood cell (WBC) count was normal. The child was hospitalized at Brazzaville and a daytime polysomnographic recording (electroencephalogram, electrooculogram, and electromyogram) was performed (Temec Vitaport 3® portable recorder) to avoid a new lumbar puncture. The child presented a complete polysomnographic syndrome of HAT with a major disturbance of the distribution of sleep and wake episodes and the occurrence of sleep onset REM periods (SOREMPs). The relapse at stage 2 was confirmed by a new CSF examination that showed an elevated WBC count (23cells·µL(-1)) with the presence of B lymphocytes. Melarsoprol treatment was undertaken. A post-treatment recording was immediately performed, showing the resolution of sleepwake pattern abnormalities. Another polysomnography, taken four months later, confirmed the normalization of sleep-wake patterns indicating healing. We therefore propose that polysomnography, being a non-invasive technique, should be used in children to alleviate burden caused by HAT staging procedures, especially regarding lumbar punctures in remote African villages.


Asunto(s)
Intoxicación por Arsénico/diagnóstico , Polisomnografía/métodos , Trastornos del Sueño-Vigilia/diagnóstico , Trastornos del Sueño-Vigilia/parasitología , Trypanosoma brucei gambiense/efectos de los fármacos , Tripanosomiasis Africana/tratamiento farmacológico , Intoxicación por Arsénico/parasitología , Intoxicación por Arsénico/prevención & control , Preescolar , Congo , Femenino , Humanos , Melarsoprol/administración & dosificación , Melarsoprol/efectos adversos , Tripanocidas/administración & dosificación , Tripanocidas/efectos adversos , Trypanosoma brucei gambiense/crecimiento & desarrollo , Tripanosomiasis Africana/complicaciones , Tripanosomiasis Africana/parasitología
8.
PLoS One ; 6(3): e16891, 2011 Mar 09.
Artículo en Inglés | MEDLINE | ID: mdl-21408057

RESUMEN

BACKGROUND: Involvement of nitric oxide (NO) in the pathophysiology of human African trypanosomiasis (HAT) was analyzed in a HAT animal model (rat infected with Trypanosoma brucei brucei). With this model, it was previously reported that trypanosomes were capable of limiting trypanocidal properties carried by NO by decreasing its blood concentration. It was also observed that brain NO concentration, contrary to blood, increases throughout the infection process. The present approach analyses the brain impairments occurring in the regulations exerted by arginase and N(G), N(G)-dimethylarginine dimethylaminohydrolase (DDAH) on NO Synthases (NOS). In this respect: (i) cerebral enzymatic activities, mRNA and protein expression of arginase and DDAH were determined; (ii) immunohistochemical distribution and morphometric parameters of cells expressing DDAH-1 and DDAH-2 isoforms were examined within the diencephalon; (iii) amino acid profiles relating to NOS/arginase/DDAH pathways were established. METHODOLOGY/PRINCIPAL FINDINGS: Arginase and DDAH activities together with mRNA (RT-PCR) and protein (western-blot) expressions were determined in diencephalic brain structures of healthy or infected rats at various days post-infection (D5, D10, D16, D22). While arginase activity remained constant, that of DDAH increased at D10 (+65%) and D16 (+51%) in agreement with western-blot and amino acids data (liquid chromatography tandem-mass spectrometry). Only DDAH-2 isoform appeared to be up-regulated at the transcriptional level throughout the infection process. Immunohistochemical staining further revealed that DDAH-1 and DDAH-2 are contained within interneurons and neurons, respectively. CONCLUSION/SIGNIFICANCE: In the brain of infected animals, the lack of change observed in arginase activity indicates that polyamine production is not enhanced. Increases in DDAH-2 isoform may contribute to the overproduction of NO. These changes are at variance with those reported in the periphery. As a whole, the above processes may ensure additive protection against trypanosome entry into the brain, i.e., maintenance of NO trypanocidal pressure and limitation of polyamine production, necessary for trypanosome growth.


Asunto(s)
Amidohidrolasas/metabolismo , Arginasa/metabolismo , Encéfalo/enzimología , Tripanosomiasis Africana/enzimología , Amidohidrolasas/genética , Aminoácidos/sangre , Aminoácidos/química , Animales , Arginasa/genética , Vías Biosintéticas , Encéfalo/parasitología , Encéfalo/patología , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Regulación Enzimológica de la Expresión Génica , Humanos , Isoenzimas/genética , Isoenzimas/metabolismo , Masculino , Espectrometría de Masas , Modelos Biológicos , ARN Mensajero/genética , ARN Mensajero/metabolismo , Ratas , Ratas Wistar , Trypanosoma brucei brucei , Tripanosomiasis Africana/sangre , Tripanosomiasis Africana/parasitología , Tripanosomiasis Africana/patología
9.
J Clin Microbiol ; 49(1): 195-200, 2011 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-21068283

RESUMEN

Neurocysticercosis (NC), caused by the larval stage of Taenia solium, is one of the most common parasitic diseases of the central nervous system. The diagnosis of NC is mostly based on costly brain neuroimaging (computed tomography and/or nuclear magnetic resonance), which is rarely accessible in most affected areas. The most sensitive and specific tools for NC diagnosis are imagery techniques. The identification of specific antibodies and antigens is currently used only to support NC diagnosis due to their limited specificity and sensitivity. This study was performed to compare immunodiagnostic assays (antibody detection by enzyme-linked immunosorbent assay [ELISA] and enzyme-linked immunoelectrotransfer blotting [EITB] and HP10 antigen detection by ELISA) with the detection of parasite DNA by PCR amplification of a repetitive element of the parasite genome in the cerebrospinal fluid (CSF) of 121 radiologically and clinically characterized NC patients. Patients were divided into six groups according to the stage of the parasites and their localization. The CSF cellularity of each patient was also recorded. When all patients were considered, PCR exhibited the highest sensitivity (95.9%) and variable specificity (80% or 100%) depending on the controls used. The sensitivities of antibody detection by ELISA and EITB were not significantly different, and ELISA identified HP10 antigen mostly when vesicular cysticerci were located in the subarachnoideal basal cisterns. These results can help in the selection of different individual assays or combinations of assays to be used in NC diagnosis according to different requirements.


Asunto(s)
Anticuerpos Antihelmínticos/líquido cefalorraquídeo , Antígenos Helmínticos/líquido cefalorraquídeo , Líquido Cefalorraquídeo/parasitología , Pruebas Diagnósticas de Rutina/métodos , Neurocisticercosis/diagnóstico , Parasitología/métodos , Taenia solium/aislamiento & purificación , Adolescente , Adulto , Anciano , Animales , Líquido Cefalorraquídeo/química , Femenino , Humanos , Inmunoensayo/métodos , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa/métodos , Sensibilidad y Especificidad , Taenia solium/química , Taenia solium/genética , Adulto Joven
10.
PLoS One ; 5(2): e9211, 2010 Feb 16.
Artículo en Inglés | MEDLINE | ID: mdl-20169057

RESUMEN

BACKGROUND: The implication of nitric oxide (NO) in the development of human African trypanosomiasis (HAT) using an animal model, was examined. The manner by which the trypanocidal activity of NO is impaired in the periphery and in the brain of rats infected with Trypanosoma brucei brucei (T. b. brucei) was analyzed through: (i) the changes occurring in NO concentration in both peripheral (blood) and cerebral compartments; (ii) the activity of nNOS and iNOS enzymes; (iii) identification of the brain cell types in which the NO-pathways are particularly active during the time-course of the infection. METHODOLOGY/PRINCIPAL FINDINGS: NO concentration (direct measures by voltammetry) was determined in central (brain) and peripheral (blood) compartments in healthy and infected animals at various days post-infection: D5, D10, D16 and D22. Opposite changes were observed in the two compartments. NO production increased in the brain (hypothalamus) from D10 (+32%) to D16 (+71%), but decreased in the blood from D10 (-22%) to D16 (-46%) and D22 (-60%). In parallel with NO measures, cerebral iNOS activity increased and peaked significantly at D16 (up to +700%). However, nNOS activity did not vary. Immunohistochemical staining confirmed iNOS activation in several brain regions, particularly in the hypothalamus. In peritoneal macrophages, iNOS activity decreased from D10 (-83%) to D16 (-65%) and D22 (-74%) similarly to circulating NO. CONCLUSION/SIGNIFICANCE: The NO changes observed in our rat model were dependent on iNOS activity in both peripheral and central compartments. In the periphery, the NO production decrease may reflect an arginase-mediated synthesis of polyamines necessary to trypanosome growth. In the brain, the increased NO concentration may result from an enhanced activity of iNOS present in neurons and glial cells. It may be regarded as a marker of deleterious inflammatory reactions.


Asunto(s)
Encéfalo/metabolismo , Modelos Animales de Enfermedad , Óxido Nítrico/biosíntesis , Tripanosomiasis Africana/metabolismo , Animales , Astrocitos/enzimología , Encéfalo/parasitología , Encéfalo/patología , Células Cultivadas , Técnicas Electroquímicas , Activación Enzimática , Técnica del Anticuerpo Fluorescente , Interacciones Huésped-Parásitos , Humanos , Inmunohistoquímica , Macrófagos Peritoneales/enzimología , Masculino , Microglía/enzimología , Neuronas/enzimología , Óxido Nítrico/sangre , Óxido Nítrico Sintasa de Tipo I/metabolismo , Óxido Nítrico Sintasa de Tipo II/metabolismo , Ratas , Ratas Wistar , Trypanosoma brucei brucei/fisiología , Tripanosomiasis Africana/enzimología , Tripanosomiasis Africana/parasitología
11.
Trop Med Int Health ; 15(4): 454-61, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19807900

RESUMEN

OBJECTIVES: In human African trypanosomiasis (HAT, sleeping sickness), staging of disease and treatment follow-up relies on white cell count in the cerebrospinal fluid (CSF). As B lymphocytes (CD19 positive cells) are not found in the CSF of healthy individuals but occur in neurological disorders such as multiple sclerosis, B lymphocyte count may be useful for field diagnosis/staging and therapeutic follow-up in HAT. METHODS: Seventy-one HAT patients were diagnosed and 50 were followed-up 6-24 months after treatment. White cell counts were used for conventional staging (stage 1, < or =5 cells/microl CSF, n = 42; stage 2, > or =20 cells/microl, n = 16) and intermediate stage (6-19 cells/microl, n = 13). Slides containing 1 microl of CSF mixed with Dynabeads CD19 pan B were examined microscopically to detect B cell rosettes (bound to at least four beads). RESULTS: Stage 1 patients exhibited zero (n = 37) or one CSF rosette/microl (n = 5), contrary to most stage 2 patients (14/16: > or =2 rosettes/microl). Intermediate stage patients expressed 0 (n = 9), 1 (n = 3) or 2 (n = 1) rosettes/microl of CSF. During follow-up, rosette counts correlated with white cell count staging but were much easier to read. CONCLUSION: B cell rosettes being easily detected in the CSF in field conditions may be proposed to replace white cell count for defining HAT stages 1 and 2 and limit uncertainty in treatment decision in patients with intermediate stage.


Asunto(s)
Linfocitos B/citología , Tripanosomiasis Africana/líquido cefalorraquídeo , Tripanosomiasis Africana/diagnóstico , Anticuerpos Antiprotozoarios/líquido cefalorraquídeo , Antígenos CD19/inmunología , Biomarcadores/líquido cefalorraquídeo , Estudios de Seguimiento , Humanos , Recuento de Linfocitos/métodos , Análisis de Regresión , Formación de Roseta/métodos , Trypanosoma brucei gambiense/aislamiento & purificación , Tripanosomiasis Africana/clasificación , Tripanosomiasis Africana/inmunología
12.
PLoS One ; 4(7): e6184, 2009 Jul 08.
Artículo en Inglés | MEDLINE | ID: mdl-19584913

RESUMEN

Human African trypanosomiasis (HAT) is a deadly vector-born disease caused by an extracellular parasite, the trypanosome. Little is known about the cellular immune responses elicited by this parasite in humans. We used multiparameter flow cytometry to characterize leukocyte immunophenotypes in the blood and cerebrospinal fluid (CSF) of 33 HAT patients and 27 healthy controls identified during a screening campaign in Angola and Gabon. We evaluated the subsets and activation markers of B and T lymphocytes. Patients had a higher percentage of CD19+ B lymphocytes and activated B lymphocytes in the blood than did controls, but lacked activated CD4+ T lymphocytes (CD25+). Patients displayed no increase in the percentage of activated CD8+ T cells (HLA-DR+, CD69+ or CD25+), but memory CD8 T-cell levels (CD8+CD45RA2) were significantly lower in patients than in controls, as were effector CD8 T-cell levels (CD8+CD45RA+CD62L2). No relationship was found between these blood immunophenotypes and disease severity (stage 1 vs 2). However, CD19+ B-cell levels in the CSF increased with disease severity. The patterns of T and B cell activation in HAT patients suggest that immunomodulatory mechanisms may operate during infection. Determinations of CD19+ B-cell levels in the CSF could improve disease staging.


Asunto(s)
Inmunofenotipificación , Linfocitos/inmunología , Tripanosomiasis Africana/inmunología , Adolescente , Adulto , Angola , Estudios de Casos y Controles , Niño , Femenino , Citometría de Flujo , Gabón , Humanos , Memoria Inmunológica , Masculino , Persona de Mediana Edad , Subgrupos de Linfocitos T , Adulto Joven
13.
Trop Med Int Health ; 14(5): 529-34, 2009 May.
Artículo en Inglés | MEDLINE | ID: mdl-19298637

RESUMEN

OBJECTIVES: To determine the role of the B-cell attracting chemokine CXCL-13, which may initiate B-cell trafficking and IgM production in diagnosing HAT meningo-encephalitis. METHODS: We determined CXCL-13 levels by ELISA on paired sera and CSF of 26 patients from Angola and of 16 controls (six endemic and ten non-endemic). Results were compared to standard stage determination markers and IgM intrathecal synthesis. RESULTS: CXCL-13 levels in patients' sera had a median value of 386.6 pg/ml and increased levels were associated with presence of trypanosomes in the CSF but not with other stage markers. CXCL-13 levels in patients' CSF had a median value of 80.9 pg/ml and increased levels were associated with all standard stage determination markers and IgM intrathecal synthesis. CONCLUSION: CXCL-13 levels in CSF increased significantly during the course of HAT. Hence the value of CXCL-13 for diagnosis, follow-up or as a marker of disease severity should be tested in a well-defined cohort study.


Asunto(s)
Infecciones Protozoarias del Sistema Nervioso Central/sangre , Quimiocina CXCL13/sangre , Encefalitis/sangre , Meningitis/sangre , Tripanosomiasis Africana/sangre , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Angola/epidemiología , Linfocitos B/metabolismo , Biomarcadores/sangre , Infecciones Protozoarias del Sistema Nervioso Central/diagnóstico , Infecciones Protozoarias del Sistema Nervioso Central/epidemiología , Niño , Encefalitis/epidemiología , Encefalitis/parasitología , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Masculino , Meningitis/epidemiología , Meningitis/parasitología , Persona de Mediana Edad , Tripanosomiasis Africana/diagnóstico , Tripanosomiasis Africana/epidemiología , Adulto Joven
14.
Cell Microbiol ; 10(1): 88-99, 2008 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-17672865

RESUMEN

The protozoan responsible for Chagas' disease, Trypanosoma cruzi, expresses on its surface an unusual trans-sialidase enzyme thought to play an important role in host-parasite interactions. Trans-sialidase is the product of a multigene family encoding both active and inactive proteins. We have demonstrated that despite lacking enzymatic activity due to a single mutation, Tyr342-His, inactive trans-sialidase displays sialic acid binding activity, with identical specificity to that of its active analogue. In this work we demonstrate that binding of a recombinant inactive trans-sialidase to molecules containing alpha2,3-linked sialic acid on endothelial cell surface triggers NF-kappaB activation, expression of adhesion molecules and upregulation of parasite entry into host cells. Furthermore, inactive recombinant trans-sialidase blocks endothelial cell apoptosis induced by growth factor deprivation. These results suggest that inactive members of the trans-sialidase family play a role in endothelial cell responses to T. cruzi infection.


Asunto(s)
Células Endoteliales/parasitología , Glicoproteínas/metabolismo , Neuraminidasa/metabolismo , Proteínas Protozoarias/metabolismo , Trypanosoma cruzi/enzimología , Trypanosoma cruzi/fisiología , Sustitución de Aminoácidos/genética , Animales , Apoptosis/inmunología , Moléculas de Adhesión Celular/biosíntesis , Línea Celular , Glicoproteínas/genética , Glicoproteínas/inmunología , Humanos , Proteínas Mutantes/genética , Proteínas Mutantes/inmunología , Proteínas Mutantes/metabolismo , Mutación Missense , Ácido N-Acetilneuramínico/metabolismo , FN-kappa B/metabolismo , Neuraminidasa/genética , Neuraminidasa/inmunología , Mutación Puntual , Unión Proteica , Proteínas Protozoarias/genética , Proteínas Protozoarias/inmunología , Proteínas Recombinantes/genética , Proteínas Recombinantes/inmunología , Proteínas Recombinantes/metabolismo , Trypanosoma cruzi/genética
15.
An Acad Bras Cienc ; 78(4): 645-65, 2006 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17143404

RESUMEN

Major modifications of immune system have been observed in African trypanosomiasis. These immune reactions do not lead to protection and are also involved in immunopathology disorders. The major surface component (variable surface glycoprotein,VSG) is associated with escape to immune reactions, cytokine network dysfunctions and autoantibody production. Most of our knowledge result from experimental trypanosomiasis. Innate resistance elements have been characterised. In infected mice, VSG preferentially stimulates a Th 1-cell subset. A response of gamma delta and CD8 T cells to trypanosome antigens was observed in trypanotolerant cattle. An increase in CD5 B cells, responsible for most serum IgM and production of autoantibodies has been noted in infected cattle. Macrophages play important roles in trypanosomiasis, in synergy with antibodies (phagocytosis) and by secreting various molecules (radicals, cytokines, prostaglandins,...). Trypanosomes are highly sensitive to TNF-alpha, reactive oxygen and nitrogen intermediates. TNF-alpha is also involved in cachexia. IFN-gamma acts as a parasite growth factor. These various elements contribute to immunosuppression. Trypanosomes have learnt to use immune mechanisms to its own profit. Recent data show the importance of alternative macrophage activation, including arginase induction. L-ornithine produced by host arginase is essential to parasite growth. All these data reflect the deep insight into the immune system realised by trypanosomes and might suggest interference therapeutic approaches.


Asunto(s)
Tripanosomiasis Africana/inmunología , Tripanosomiasis Africana/patología , Animales , Autoanticuerpos/inmunología , Bovinos , Citocinas/inmunología , Humanos , Macrófagos/inmunología , Ratones , Linfocitos T/inmunología , Glicoproteínas Variantes de Superficie de Trypanosoma/inmunología
16.
An. acad. bras. ciênc ; 78(4): 645-665, Dec. 2006. ilus
Artículo en Inglés | LILACS | ID: lil-438568

RESUMEN

Major modifications of immune system have been observed in African trypanosomiasis. These immune reactions do not lead to protection and are also involved in immunopathology disorders. The major surface component (variable surface glycoprotein,VSG) is associated with escape to immune reactions, cytokine network dysfunctions and autoantibody production. Most of our knowledge result from experimental trypanosomiasis. Innate resistance elements have been characterised. In infected mice, VSG preferentially stimulates a Th 1-cell subset. A response of gd and CD8 T cells to trypanosome antigens was observed in trypanotolerant cattle. An increase in CD5 B cells, responsible for most serum IgM and production of autoantibodies has been noted in infected cattle. Macrophages play important roles in trypanosomiasis, in synergy with antibodies (phagocytosis) and by secreting various molecules (radicals, cytokines, prostaglandins,...). Trypanosomes are highly sensitive to TNF-alpha, reactive oxygen and nitrogen intermediates. TNF-alpha is also involved in cachexia. IFN-gamma acts as a parasite growth factor. These various elements contribute to immunosuppression. Trypanosomes have learnt to use immune mechanisms to its own profit. Recent data show the importance of alternative macrophage activation, including arginase induction. L-ornithine produced by host arginase is essential to parasite growth. All these data reflect the deep insight into the immune system realised by trypanosomes and might suggest interference therapeutic approaches.


Modificações importantes no sistema imune são observadas na tripanosomíase Africana. Essas reações imunológicas não protegem e estão envolvidas em distúrbios imunopatológicos. O principal componente de superfície (glicoproteína variante de superfície, VSG) está associado à evasão das respostas imune, às disfunções da rede de citocinas e à produção de autoanticorpos. Muitos de nossos conhecimentos resultam da tripanosomíase experimental. Componentes da imunidade inata estão sendo caracterizados. Em camundongos infectados, a VSG estimula preferencialmente células Th1. Uma resposta de gd e células T CD8 aos antígenos do tripanossoma foi observada em gado tripanotolerante. Um aumento em células B CD5, responsável por IgM sérica e produção de autoanticorpos, foi observado no gado infectado. Os macrófagos desempenham importantes funções na tripanosomíase, em sinergismo com anticorpos (fagocitose) e pela secreção de várias moléculas (radicais, citocinas, prostaglandinas). Tripanossomas são altamente sensíveis ao TNF-alfa, espécies reativas de oxigênio e nitrogênio. O TNF-alfa também está envolvido em caquexia. O IFN-gama atua como um fator de crescimento do parasita. Esses vários componentes contribuem para a imunossupressão. Os tripanossomas usam os mecanismos imunes para seu próprio benefício. Dados recentes mostram a importância da ativação alternativa de macrófagos, incluindo a indução pela arginase. A L-ornitina produzida pela arginase do hospedeiro é essencial para o crescimento do parasita. Todos esses dados mostram o envolvimento no sistema imune realizado pelos tripanossomas e sugerem a interferência de métodos terapêuticos.


Asunto(s)
Animales , Bovinos , Humanos , Ratones , Tripanosomiasis Africana/inmunología , Tripanosomiasis Africana/patología , Autoanticuerpos/inmunología , Citocinas/inmunología , Macrófagos/inmunología , Linfocitos T/inmunología , Glicoproteínas Variantes de Superficie de Trypanosoma/inmunología
17.
Int J Parasitol ; 36(9): 1057-65, 2006 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-16765963

RESUMEN

Trypanosoma brucei gambiense infection is an important public health challenge in sub-Saharan Africa. This parasitic disease is difficult to diagnose due to insidious clinical signs and transient parasitaemias. The clinical course is marked by two stages of increasing disease severity. An early systemic parasitic invasion is followed by the development of a progressive meningo-encephalitis. During this latter stage, a broad spectrum of neurological signs appears, which finally lead to a demyelinating and fatal stage if untreated. Treatment is toxic and difficult to administer when the CNS is invaded. Therefore, accurate diagnostic methods for stage determination are needed. The classically used criteria are not sufficiently specific and mechanisms of parasite invasion through the blood-brain barrier remain poorly understood. As cytokines/chemokines are involved in the early recruitment of leukocytes into the CNS, this study has focused on their potential value to define the onset of CNS involvement. Levels of monocyte chemoattractant protein-1/CCL-2, macrophage inflammatory protein-1alpha/CCL-3, IL-8/CXCL-8, regulated upon activation T cell expressed and secreted (RANTES)/CCL-5 and IL-1beta were measured in paired sera and CSF from 57 patients and four controls. Patients were classified into three groups (stage 1, intermediate and stage 2) according to current field criteria for stage determination (CSF cell count, presence of trypanosomes in CSF and neurological signs). In sera, cytokine/chemokine levels were poorly related to disease stage. Only CXCL-8 was higher in stage 1 patients when compared with stage 2 and CCL-5 was higher in controls when compared with patients. In contrast, in CSF the expression of the selected cytokines, except CCL-5, was associated with the presence of neurological signs, demonstrating their diagnostic value. We observed a relationship between the presence of trypanosomes or trypanosome-related compounds in CSF and levels of IL-1beta, CXCL-8, CCL-2 and CCL-3. These cytokines and chemokines may be triggered by the parasite and hence are potential markers of CNS invasion.


Asunto(s)
Infecciones Protozoarias del Sistema Nervioso Central/diagnóstico , Quimiocinas/análisis , Trypanosoma brucei gambiense/aislamiento & purificación , Tripanosomiasis Africana/diagnóstico , Adolescente , Adulto , Animales , Biomarcadores/sangre , Biomarcadores/líquido cefalorraquídeo , Barrera Hematoencefálica , Quimiocinas/sangre , Quimiocinas/líquido cefalorraquídeo , Niño , Citocinas/sangre , Citocinas/líquido cefalorraquídeo , Progresión de la Enfermedad , Ensayo de Inmunoadsorción Enzimática/métodos , Humanos , Persona de Mediana Edad , Índice de Severidad de la Enfermedad
18.
Trends Parasitol ; 22(1): 17-20, 2006 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-16307906

RESUMEN

Epilepsy and onchocerciasis (river blindness) constitute serious public health problems in several tropical countries. There are four main mechanisms that might explain a relationship between these two diseases: (i) the presence of Onchocerca volvulus in the central nervous system; (ii) the pathogenicity of various O. volvulus strains; (iii) immunological mechanisms involving cross-reactive immunization or cytokine production during infection; and (iv) the triggering role of insomnia due to itching.


Asunto(s)
Infecciones Parasitarias del Sistema Nervioso Central/complicaciones , Epilepsia/parasitología , Onchocerca volvulus/patogenicidad , Oncocercosis Ocular/complicaciones , Oncocercosis Ocular/parasitología , Animales , Causalidad , Infecciones Parasitarias del Sistema Nervioso Central/epidemiología , Infecciones Parasitarias del Sistema Nervioso Central/inmunología , Infecciones Parasitarias del Sistema Nervioso Central/parasitología , Citocinas/inmunología , Epilepsia/epidemiología , Humanos , Onchocerca volvulus/inmunología , Oncocercosis Ocular/epidemiología , Oncocercosis Ocular/inmunología , Trastornos del Inicio y del Mantenimiento del Sueño/complicaciones
19.
Chemotherapy ; 52(1): 16-9, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-16340192

RESUMEN

Human African trypanosomiasis remains a difficult health problem to treat because of the few compounds available nowadays and their toxicity. The disease also affects animals and is therefore responsible for economic difficulties and zoonotic risks. There is an urgent need to develop new drugs for treatment of African trypanosomiasis. Methylene blue is a safe and easy-to-use drug employed in human therapy. It is also known to have antimalarial activity. In this study, methylene blue trypanocidal activity was found in vitro but it failed to cure trypanosome infection in mice when administered at 300 mg/kg p.o.or at 200 mg/kg i.p. Differences between in vitro and in vivo activities are discussed, and further in-depth studies are warranted.


Asunto(s)
Azul de Metileno/farmacología , Tripanocidas/farmacología , Animales , Modelos Animales de Enfermedad , Femenino , Concentración 50 Inhibidora , Azul de Metileno/administración & dosificación , Ratones , Insuficiencia del Tratamiento , Tripanocidas/administración & dosificación , Trypanosoma brucei brucei/efectos de los fármacos , Trypanosoma brucei rhodesiense/efectos de los fármacos , Tripanosomiasis Africana/tratamiento farmacológico , Tripanosomiasis Africana/parasitología
20.
Rev Prat ; 56(20): 2209-16, 2006 Dec 31.
Artículo en Francés | MEDLINE | ID: mdl-17352316

RESUMEN

Trypanosomiases are imported and rare parasitosis on the French metropolitan territory. They are re-emerging in some endemic areas, and their mode of transmission can lead to an increase of imported cases in a near future. They can be responsible for serious disease. In this paper, we describe the basic data concerning epidemiology, clinical features, diagnosis, treatment and prevention of sleeping sickness (Africa) and Chagas disease (Latin America).


Asunto(s)
Tripanosomiasis/transmisión , Animales , Enfermedad de Chagas/diagnóstico , Enfermedad de Chagas/tratamiento farmacológico , Enfermedad de Chagas/transmisión , Enfermedades Endémicas , Humanos , Tripanocidas/uso terapéutico , Trypanosoma/clasificación , Trypanosoma/fisiología , Tripanosomiasis/diagnóstico , Tripanosomiasis/tratamiento farmacológico , Tripanosomiasis Africana/diagnóstico , Tripanosomiasis Africana/tratamiento farmacológico , Tripanosomiasis Africana/transmisión
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...